[go: up one dir, main page]

MXPA02008722A - Inhibidores novedosos de aril fructosa-1,6-bisfosfatasa. - Google Patents

Inhibidores novedosos de aril fructosa-1,6-bisfosfatasa.

Info

Publication number
MXPA02008722A
MXPA02008722A MXPA02008722A MXPA02008722A MXPA02008722A MX PA02008722 A MXPA02008722 A MX PA02008722A MX PA02008722 A MXPA02008722 A MX PA02008722A MX PA02008722 A MXPA02008722 A MX PA02008722A MX PA02008722 A MXPA02008722 A MX PA02008722A
Authority
MX
Mexico
Prior art keywords
fructose
novel aryl
bisphosphatase inhibitors
inhibitors
novel
Prior art date
Application number
MXPA02008722A
Other languages
English (en)
Inventor
Qun Dang
Original Assignee
Metabasis Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabasis Therapeutics Inc filed Critical Metabasis Therapeutics Inc
Publication of MXPA02008722A publication Critical patent/MXPA02008722A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3808Acyclic saturated acids which can have further substituents on alkyl
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3826Acyclic unsaturated acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6536Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
    • C07F9/6539Five-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen inhibidores novedosos de FBPasa de la formula (I) que son utiles en el tratamiento de la diabetes y otras condiciones asociadas con glucosa elevada en la sangre.
MXPA02008722A 2000-03-08 2001-03-07 Inhibidores novedosos de aril fructosa-1,6-bisfosfatasa. MXPA02008722A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18775000P 2000-03-08 2000-03-08
PCT/US2001/007452 WO2001066553A2 (en) 2000-03-08 2001-03-07 Novel aryl fructose-1,6-bisphosphatase inhibitors

Publications (1)

Publication Number Publication Date
MXPA02008722A true MXPA02008722A (es) 2004-05-05

Family

ID=22690309

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02008722A MXPA02008722A (es) 2000-03-08 2001-03-07 Inhibidores novedosos de aril fructosa-1,6-bisfosfatasa.

Country Status (21)

Country Link
US (2) US6919322B2 (es)
EP (2) EP1265907B9 (es)
JP (1) JP2003525944A (es)
KR (1) KR20020079988A (es)
CN (2) CN1516705A (es)
AT (1) ATE350385T1 (es)
AU (2) AU4553201A (es)
BR (1) BR0109062A (es)
CA (1) CA2401706A1 (es)
CZ (1) CZ20023018A3 (es)
DE (1) DE60125734T2 (es)
HK (1) HK1051865A1 (es)
HU (1) HUP0300344A3 (es)
IL (2) IL151248A0 (es)
MX (1) MXPA02008722A (es)
NO (1) NO20024240L (es)
PL (1) PL357251A1 (es)
RU (1) RU2002126616A (es)
SK (1) SK12722002A3 (es)
WO (1) WO2001066553A2 (es)
ZA (1) ZA200207004B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6284748B1 (en) 1997-03-07 2001-09-04 Metabasis Therapeutics, Inc. Purine inhibitors of fructose 1,6-bisphosphatase
DK1112275T3 (da) 1998-09-09 2003-11-24 Metabasis Therapeutics Inc Hidtil ukendte heteroaromatiske inhibitorer for fructose-1,6-bisphosphatase
US6756360B1 (en) * 1998-12-24 2004-06-29 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes
RU2273642C2 (ru) * 1999-12-22 2006-04-10 Метабэйсис Терапьютикс, Инк. Бисамидатные фосфонатные соединения, являющиеся ингибиторами фруктозо-1,6-бисфосфатазы
RU2002126616A (ru) 2000-03-08 2004-03-20 Метабэйсис Терапьютикс, Инк. (Us) Новые арильные ингибиторы фруктозо-1, 6-бисфосфатазы
US7563774B2 (en) * 2000-06-29 2009-07-21 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
TW200409643A (en) * 2002-07-23 2004-06-16 Sankyo Co Preventive agents for diabetes mellitus
FR2846327B1 (fr) * 2002-10-25 2006-03-24 Merck Sante Sas Derives de n-benzodioxolyl, n-benzodioxanyl et n-benzodioxepinyl arylcarboxamides utilisables dans le traitement de dyslipidemies et compositions pharmaceutiques les contenant.
US7129049B2 (en) * 2003-12-22 2006-10-31 Regents Of The University Of Minnesota Method of detecting equine glycogen storage disease IV
WO2006023515A2 (en) * 2004-08-18 2006-03-02 Metabasis Therapeutics, Inc. Novel thiazole inhibitors of fructose 1,6-bisphosphatase
CN101119748A (zh) * 2004-12-13 2008-02-06 第一三共株式会社 用于治疗糖尿病的药物组合物
WO2006064826A1 (ja) * 2004-12-15 2006-06-22 Daiichi Sankyo Company, Limited FBPase阻害剤を含有する医薬組成物
EP1752450A1 (en) 2005-08-01 2007-02-14 Merck Sante Imidazole derivatives as fructose-1,6-bisphosphatase inhibitors and pharmaceutical compositions containing them
CN101821276B (zh) * 2007-08-13 2016-08-31 症变治疗公司 新颖的葡糖激酶活化剂
EP2058308A1 (fr) 2007-11-12 2009-05-13 Merck Sante Dérivés de benzimidazoledihydrothiadiazinone comme inhibiteurs de fructose-1,6-biphosphatase et compositions pharmaceutiques les contenant.
DK3366686T3 (da) 2009-03-20 2020-11-23 Metabasis Therapeutics Inc Inhibitorer af diacylglycerol-o-acyltransferase 1 (dgat-1) og anvendelser deraf
US9006568B2 (en) 2012-02-15 2015-04-14 Phillips 66 Company Synthesis of photovoltaic conjugated polymers
WO2013156559A1 (en) * 2012-04-20 2013-10-24 Bayer Cropscience Ag N-cycloalkyl-n-[(heterocyclylphenyl)methylene]-(thio)carboxamide derivatives
CN103665043B (zh) 2012-08-30 2017-11-10 江苏豪森药业集团有限公司 一种替诺福韦前药及其在医药上的应用
WO2014088795A1 (en) 2012-12-03 2014-06-12 Phillips 66 Company Benzo [1,2-b:4,5-b'] dithiophene-thienothiophene based conjugated polymers
EP3078378B1 (en) 2015-04-08 2020-06-24 Vaiomer Use of factor xa inhibitors for regulating glycemia
US9911919B2 (en) 2015-10-01 2018-03-06 Phillips 66 Company Process of manufacturing an electron transport material
US10418555B2 (en) 2015-10-01 2019-09-17 Phillips 66 Company Formation of films for organic photovoltaics
US10099963B2 (en) 2015-10-01 2018-10-16 Phillips 66 Company Formation of films for organic photovoltaics
US10312448B2 (en) 2015-10-01 2019-06-04 Phillips 66 Company Process of manufacturing an electron transport material
US9905769B2 (en) 2015-10-01 2018-02-27 Phillips 66 Company Process of manufacturing an electron transport material
US10604541B2 (en) 2016-07-22 2020-03-31 Bristol-Myers Squibb Company Glucokinase activators and methods of using same
CN111116647B (zh) * 2019-12-02 2021-08-24 西安电子科技大学 一种具有hdac抑制活性的磷酸类化合物及其制备方法与用途

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL72851C (es) * 1950-10-31 1900-01-01
US2683168A (en) * 1950-12-22 1954-07-06 California Research Corp Preparation of organo phosphonyl chlorides
US3524846A (en) 1967-06-02 1970-08-18 Syntex Corp Process for the didealkylation of phosphonate esters
GB2043073B (en) * 1979-02-13 1983-05-11 Symphar Sa Mono-and diphosphonate compounds
US4640701A (en) * 1984-04-17 1987-02-03 Ciba-Geigy Corporation Herbicidal phosphonic acid and phosphinic acid derivatives
US4746653A (en) * 1986-02-28 1988-05-24 Ciba-Geigy Corporation Certain hetero phosphonic acid derivatives of 2-piperidine or 2-tetrahydropyridinecarboxylates and esters thereof which are useful for the treatment of disorders responsive to blockade of the NMDA receptor in mammals
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
DE3770982D1 (de) * 1986-04-24 1991-08-01 Fujisawa Pharmaceutical Co Diphosphonsaeure-verbindungen, verfahren zu deren herstellung und sie enthaltende arzneimittel.
US5091552A (en) 1986-06-30 1992-02-25 Board Of Regents, The University Of Texas System Novel antitumor aldophosphamide analogs
US5045557A (en) * 1987-03-20 1991-09-03 Schering Agrochemicals Ltd. Imidazable fungicides and use thereof
US4943629A (en) 1988-08-12 1990-07-24 American Cyanamid Company Antidiabetic alpha-substituted phosphonates
US4968790A (en) 1988-08-12 1990-11-06 American Cyanamid Company Antidiabetic phosphates
DE69014562T2 (de) 1989-01-24 1995-06-22 Gensia Pharma Verfahren und verbindungen zur verabreichung von aica ribosiden und zur erniedrigung des blutglucose gehaltes.
US5658889A (en) 1989-01-24 1997-08-19 Gensia Pharmaceuticals, Inc. Method and compounds for aica riboside delivery and for lowering blood glucose
CA2083386C (en) 1990-06-13 1999-02-16 Arnold Glazier Phosphorous prodrugs
US5157027A (en) 1991-05-13 1992-10-20 E. R. Squibb & Sons, Inc. Bisphosphonate squalene synthetase inhibitors and method
US5208235A (en) * 1992-03-10 1993-05-04 E. R. Squibb & Sons, Inc. Indole- and benzimidazole-substituted imidazole derivatives
US5278153A (en) * 1992-05-18 1994-01-11 E. R. Squibb & Sons, Inc. Aryl and heteroaryl (phosphinylmethyl)phosphonate squalene synthetase inhibitors and method
CA2145640C (en) 1992-09-28 2001-01-30 Banavara L. Mylari Substituted pyrimidines for control of diabetic complications
DE69426904T2 (de) 1993-06-29 2001-10-11 Mitsubishi Chemical Corp., Tokio/Tokyo Phosphonat-Nukleotid Ester-Derivate
BR9407510A (pt) 1993-09-17 1997-01-07 Gilead Sciences Inc Análogos de nucleotideo
US6011049A (en) 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
US6054587A (en) * 1997-03-07 2000-04-25 Metabasis Therapeutics, Inc. Indole and azaindole inhibitors of fructose-1,6-bisphosphatase
US6284748B1 (en) 1997-03-07 2001-09-04 Metabasis Therapeutics, Inc. Purine inhibitors of fructose 1,6-bisphosphatase
AU6691498A (en) * 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel benzimidazole inhibitors of fructose-1,6-bisphosphatase
US6312662B1 (en) * 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
JP4741725B2 (ja) 1998-03-06 2011-08-10 メタベイシス・セラピューティクス・インコーポレーテッド リン含有化合物のための新規なプロドラッグ
US6107274A (en) 1998-03-16 2000-08-22 Ontogen Corporation Piperazines as inhibitors of fructose-1,6-bisphosphatase (FBPase)
DK1112275T3 (da) 1998-09-09 2003-11-24 Metabasis Therapeutics Inc Hidtil ukendte heteroaromatiske inhibitorer for fructose-1,6-bisphosphatase
DE19843383A1 (de) * 1998-09-22 2000-03-30 Hassan Jomaa Phosphororganische Verbindungen und ihre Verwendung
BR9917005A (pt) * 1998-12-24 2002-04-02 Metabasis Therapeutics Inc Combinação de inibidores de fbpase e sensibilizadores de insulina para o tratamento de diabete
US6756360B1 (en) 1998-12-24 2004-06-29 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes
HUP0200260A3 (en) * 1999-03-05 2002-11-28 Metabasis Therapeutics Inc San Novel phosphorus-containing prodrugs, their preparation and their use
RU2273642C2 (ru) 1999-12-22 2006-04-10 Метабэйсис Терапьютикс, Инк. Бисамидатные фосфонатные соединения, являющиеся ингибиторами фруктозо-1,6-бисфосфатазы
ES2301142T3 (es) 2000-01-21 2008-06-16 Novartis Ag Combinaciones que comprenden inhibidores de dipeptidilpeptidasa-iv y agentes antidiabeticos.
RU2002126616A (ru) 2000-03-08 2004-03-20 Метабэйсис Терапьютикс, Инк. (Us) Новые арильные ингибиторы фруктозо-1, 6-бисфосфатазы
CY2010012I2 (el) * 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
US7563774B2 (en) 2000-06-29 2009-07-21 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
PL365779A1 (en) 2000-07-06 2005-01-10 Metabasis Therapeutics, Inc. A combination of fbpase inhibitors and antidiabetic agents useful for the treatment of diabetes
WO2006023515A2 (en) 2004-08-18 2006-03-02 Metabasis Therapeutics, Inc. Novel thiazole inhibitors of fructose 1,6-bisphosphatase

Also Published As

Publication number Publication date
AU2001245532B2 (en) 2005-08-11
KR20020079988A (ko) 2002-10-21
JP2003525944A (ja) 2003-09-02
WO2001066553A3 (en) 2002-03-14
EP1607401A1 (en) 2005-12-21
NO20024240L (no) 2002-11-08
IL151248A (en) 2007-06-17
DE60125734D1 (en) 2007-02-15
DE60125734T2 (de) 2007-10-25
HK1051865A1 (en) 2003-08-22
US20020040014A1 (en) 2002-04-04
US7371739B2 (en) 2008-05-13
ZA200207004B (en) 2003-12-01
CN1699383A (zh) 2005-11-23
ATE350385T1 (de) 2007-01-15
WO2001066553A2 (en) 2001-09-13
IL151248A0 (en) 2003-04-10
RU2002126616A (ru) 2004-03-20
PL357251A1 (en) 2004-07-26
EP1265907A2 (en) 2002-12-18
CN1516705A (zh) 2004-07-28
CA2401706A1 (en) 2001-09-13
EP1265907B9 (en) 2007-05-09
US6919322B2 (en) 2005-07-19
US20050176684A1 (en) 2005-08-11
HUP0300344A2 (hu) 2003-06-28
AU4553201A (en) 2001-09-17
SK12722002A3 (sk) 2003-04-01
NO20024240D0 (no) 2002-09-05
HUP0300344A3 (en) 2007-05-29
EP1265907B1 (en) 2007-01-03
BR0109062A (pt) 2002-11-26
CZ20023018A3 (cs) 2003-01-15

Similar Documents

Publication Publication Date Title
MXPA02008722A (es) Inhibidores novedosos de aril fructosa-1,6-bisfosfatasa.
PL346520A1 (en) Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase
WO2001047935A3 (en) Novel bisamidate phosphonate prodrugs
EG24358A (en) Isoindolin-1-one glucokinase avtivators
GB0213612D0 (en) Organic compounds
AU2904300A (en) Polysubstituted 6-phenylphenanthridines with pde-iv inhibiting activity
WO2000064422A3 (en) Novel treatment of neurotraumatic conditions with raf inhibitor
DE60011677D1 (en) Tryptase-inhibitoren
SI1244614T1 (en) Tryptase inhibitors
WO2003017925A3 (en) Treatment of type i diabetes
ZA981558B (en) Inclusion complexes in aqueous solution
SE0102385D0 (sv) Screening methods
JO2238B1 (en) Glycine stimulants iswindline 1- on
UA32320A (uk) Спосіб лікування муковісцидозу
UA34351A (uk) Спосіб визначення фізичної працездатності людини
UA50886A (uk) Спосіб комплексної обробки свердловини
UA32350A (uk) Спосіб лікування гострого інфаркту міокарда

Legal Events

Date Code Title Description
FG Grant or registration